Overlapping epidemiologies of hepatitis A and typhoid fever: The needs of the traveler

Journal of Travel Medicine

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Luxemburger, Christine ^a   Dutta, Anil K ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; TYPHOID VACCINE;

ADOLESCENT; ADULT; AFRICA; ASIA; BACTERIAL INFECTION; CHILD; DISEASE TRANSMISSION; ENDEMIC DISEASE; EUROPE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNIZATION; INFANT; MIDDLE EAST; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SALMONELLA TYPHI; SEROPREVALENCE; TRAVEL; TYPHOID FEVER; UNITED STATES; VIRUS HEPATITIS; WORLD HEALTH ORGANIZATION;

EID: 17844361938     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2005.12053     Document Type: Review

References (78)

1. Steffen R, DuPont HL. Manual of travel medicine and health. Hamilton: BC Decker, 1999.
2. Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travellers. JAMA 1994; 272:885-888.
3. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travellers: who should be targeted for prevention? Clin Infect Dis 2004; 39:186-191.
4. O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001; 33:603-609.
5. Bell BP. Global epidemiology of hepatitis A: implications for control strategies. In: Margolis HS, Alter MJ, Liang JT, Dienstag JL, eds. Viral hepatitis and liver disease. London: International Medical Press, 2002: 9-14.
6. Bell BP, Feinstone SM. Hepatitis A vaccine. Virus description. In: Plotkin S, ed. Vaccines, 4th edn. Philadelphia, PA: Saunders, 2004: 269-297.
7. Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226-233.
8. Lemon SM. The natural history of hepatitis A; the potential for transmission by blood or blood products. Vox Sang 1994; 67(suppl 4):19-23.
9. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide epidemic of hepatitis A. Epidemiol Infect 1997; 118:243-252.
10. Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000; 106:e54.
11. Lerman Y, Shohat T, Ashkenazi S, et al. Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study. Clin Infect Dis 1993; 17: 411-414.
12. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48(RR-12):1-37.
13. Hadler SC. Global impact of hepatitis A infection: changing patterns. In: Hollinger FB, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins, 1991: 14-20.
14. Frosner GG, Papaevangelou G, Butler R, et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. Am J Epidemiol 1979; 110:63-69.
15. Viral Hepatitis Prevention Board. Update on hepatitis A. Viral Hepatitis 1997; 6:1-15.
16. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine 2000; 18(suppl 1):S57-S60.
17. Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 2000; 18(suppl 1):S61-S64.
18. Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East Asia and Africa. Vaccine 2000; 18(suppl 1):S65-S67.
19. Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000; 18(suppl 1):S68-S70.
20. Jenson HB. The changing picture of hepatitis A in the United States. Curr Opin Pediatr 2004; 16:89-93.
21. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/ resource/PDFs/disease_burden2004.pdf (accessed 17 November 2004).
22. Centers for Disease Control and Prevention (CDC). Hepatitis A. Epidemiology and prevention of vaccine-preventable diseases, 6th edn. Atlanta, GA: CDC, 2001: 191-206.
23. Samadari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004; 22:4342-4250.
24. Tapia-Conyer R, Santos JI, Cavalcanti AM, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999; 61:825-829.
25. Kumate J, Alvizouri AM, Isibasi A. Serologic survey of hepatitis A antibodies in Mexican children. Bull Pan Am Health Organ 1982; 16:156-160.
26. Bartoloni A, Bartalesi F, Roselli M, et al. Prevalence of antibodies against hepatitis A and E viruses among rural populations of the Chaco region, south-eastern Bolivia. Trop Med Int Health 1999; 4:596-601.
27. Lopez H, Zitto T, Bare P, et al. Prevalence of anti-hepatitis A antibodies in an urban middle-class area of Argentina: some associated factors. Int J Infect Dis 2000; 4:34-37.
28. Bottiger M, Christenson B, Grillner L. Hepatitis A immunity in the Swedish population. A study of the prevalence of markers in the Swedish population. Scand J Infect Dis 1997; 29:99-102.
29. Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992; 10(suppl 1):S63-S66.
30. Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. Eur J Epidemiol 1999; 15:805-808.
31. Joussemet M, Depaquit J, Nicand E, et al. Fall in the seroprevalence of hepatitis A in French youth. Gastroenterol Clin Biol 1999; 23:447-452.
32. Marinho RT, Valente AR, Ramalho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. Eur J Gastroenterol Hepatol 1997; 9:795-797.
33. Beutels M, van Damme P, Aelvoet W, C et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997; 13:275-280.
34. Bruguera M, Salleras L, Plans P, et al. Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989-1996. Implications for new vaccination strategy. Med Clin (Bare) 1999; 112:406-408.
35. Amin J, Heath T, Morrell S. Hepatitis A in Australia in the 1990s: future directions in surveillance and control. Commun Dis Intell 1999; 23:113-120.
36. Person MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Epidemiol Infect 1998; 121:631-636.
37. Kunasol P, Cooksley G, Chan VF, et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Pub Health 1998; 29:255-262.
38. Sohn YM, Rho HO, Park MS, et al. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med J 2000; 41:34-39.
39. Mittal Sk, Rastogi A, Kumar N, et al. Seroprevalence of hepatitis A in children-implications for hepatitis A vaccine. Trop Gastroenterol 1998; 19:120-121.
40. Sawayama Y, Hayashi J, Ariyama I, et al. A ten year serological survey of hepatitis A. B and C viruses infections in Nepal. J Epidemiol 1999; 9:350-354.
41. Hau CH, Hien TT, Tien NT, et al. Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. Am J Trop Med Hyg 1999; 60:277-280.
42. Martin DJ, Blackburn NK, Johnson S, McAnerney JM. The current epidemiology of hepatitis A infection in South Africa: implications for vaccination. Trans R Soc Trop Med Hyg 1994; 88:288-291.
43. Kalaajieh W, Rima A, Dennaoui M, Al Khodayry R. Seroprevalence of hepatitis A antibodies in Lebanese children. Med Mal Infect 2000; 30:757-761.
44. Teitelbaum P. An estimate of the incidence of hepatitis A in unimmunized Canadian travelers to developing countries. J Travel Med 2004; 11:102-106.
45. Parry CM. Typhoid fever. Curr Infect Dis Rep 2004; 6:27-33.
46. Parry CM. The treatment of multidrug-resistaut and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98:413-422.
47. Levine MM. Typhoid fever vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edn. Philadelphia, PA: Saunders, 2004: 1057-1093.
48. World Health Organization. Immunization, vaccines and biologicals: typhoid fever. Geneva: WHO, 1998.
49. Parry CM, Hoa NJ, Diep TS, et al. Value of a single-tube Widal test in diagnosis of typhoid fever in Vietnam. J Clin Microbiol 1999; 37:2882-2886.
50. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-349.
51. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-353.
52. Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-737.
53. Lin FY, Vo AH, Phan VB, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000; 62:644-648.
54. Duggan MB, Beyer L. Enteric fever in young Yoruba children. Arch Dis Child 1975; 50:67-71.
55. Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev Infect Dis 1991; 13:85-90.
56. Green SD, Cheesebrough JS. Salmonella bacteraemia among young children at a rural hospital in western Zaire. Ann Trop Paediatr 1993; 13:45-53.
57. Bhutta ZA. Impact of age and drug resistance on mortality in typhoid fever. Arch Dis Child 1996; 75:214-217.
58. Black RE, Cisneros L, Levine MM. et al. Case-control study to identify risk factors for paediatric endemic typhoid fever in Santiago, Chile. Bull World Health Organ 1985; 63:899-904.
59. Castillo MTG, Superable JT, Magpantay RL, et al. Case-control study of resistant Salmonella Typhi in Metro Manila, Philippines. Southeast Asian J Trop Med Public Health 1995; 26(suppl 2):39-41.
60. Luby SP, Faizan MK, Fisher-Hoch SP, et al. Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. Epidemiol Infect 1998; 120:129-138.
61. Velema JP, van Wijnen G, Bult P, et al. Typhoid fever in Ujung Pandang, Indonesia-high-risk groups and high-risk behaviours. Trop Med Int Health 1997; 2:1088-1094.
62. Luxemburger C, Chau MC, Mai NL, et al. Risk factors for typhoid fever in the Mekong delta, southern Viet Nam: a case-control study. Trans R Soc Trop Med Hyg 2001; 95:19-23.
63. Vollaard AM, Ali S, van Asten HA, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 2004; 291:2607-2615.
64. Anonymous. Typhoid and paratyphoid fevers. Office Population Census Surveys Monitor 1985; MB2 85/2:9-11.
65. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633-638.
66. Fica AE, Prat-Miranda S, Fernandez-Ricci A, et al. Epidemic typhoid in Chile: analysis by molecular and conventional methods of Salmonella typhi strain diversity in epidemic (1977 and 1981) and nonepidemic (1990) years. J Clin Microbiol 1996; 34:1701-1707.
67. Mermin JH, Villar R, Carpenter J, et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikstan associated with consumption of municipal water. J Infect Dis 1999; 179:1416-1422.
68. Carmeli Y, Schapiro JM, Alkan M. Typhoid fever in Ethiopian immigrants to Israel and native-born Israelis: a comparative study. Clin Infect Dis 1993; 16:213-215.
69. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997; 24(suppl 1):S106-S109.
70. Parry C, Wain J, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351:1289.
71. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 16:10-16.
72. Centers for Disease Control and Prevention. Typhoid immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994; 43(RR-14):1-7.
73. Vodopija I, Baklaic Z, Clemens R. Immune response to hepatitis A vaccine combined or given simultaneously with typhoid fever vaccine. J Travel Med 1997; 4:114-117.
74. Van Herck K, Zuckerman J, Castelli F, et al. Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med 2003; 10:75-79.
75. Lobermann M, Kollaritsch H, Ziegler T, et al. A randomized open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther 2004; 26:1084-1091.
76. Beran J, Beutels M, Levie K, et al. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J Travel Med 2000; 7:246-252.
77. Beeching NJ, Clarke PD, Kitchin NRE, et al. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 2004; 23:29-35.
78. Beran J, Chlibek R, Weber F. A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 2003; 21:4650-4654.